TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03481270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concordant
Description: We will be randomizing across providers - we are particularly interested in racial concordance.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Concordant
Description: We will be randomizing across providers - we are particularly interested in racial concordance.
Study: NCT03880877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (TA6/TA6)
Description: The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (TA6/TA7)
Description: The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (TA7/TA7)
Description: The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin and 5-FU
Description: Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)
Study: NCT02129426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Sedation medication
Study: NCT04438707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Method combined with Therapeutic exercice.
Description: Children must perform specific exercices in this combined method with the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: Children must perform specific exercices without the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
Study: NCT02825290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate
Study: NCT04308733

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: patients will be stimulated over the contralateral pharyngeal motor cortex with anodal tDCS (2mA, 20 minutes) for 4 consecutive days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Anodal tDCS
Description: patients will be stimulated over the contralateral pharyngeal motor cortex with anodal tDCS (2mA, 20 minutes) for 4 consecutive days
Study: NCT04348227

Intervention type: BEHAVIORAL
Intervention: Enhanced hygiene measures
Description: Wether or not hygiene measures dictated by the pandemic of severe acute respiratory syndrome coronavirus 19 , reduce multi drug resistant pathogens isolated in endotracheal aspirates.
Study: NCT01129583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Injection into the biceps brachii and brachialis immediately following the initial fracture surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
Study: NCT02898285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team sports
Description: Participants will choose from a list of team sports and will be signed up with the team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual sport condition
Description: Participants will choose from a list of individual sports.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Night out
Description: Participants in this group will be asked to go out to have a weekly night out or personal time of choice, such as dinner or a movie (only restrictions are they cannot go do a sport or physical activity and time must be spent without children).
Study: NCT03515291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iMP cells
Description: Immunomodulatory progenitor cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control injection
Description: Cell suspension solution
Study: NCT03787381

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: Vaginal ultrasound examination
Study: NCT03873675

Intervention type: DIAGNOSTIC_TEST
Intervention: parathyroid hormone
Description: 10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient
Study: NCT00866008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation
Description: 1. Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~2. Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation
Description: 1. Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~2. Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
Study: NCT02876250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
Study: NCT03501927

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS (focused cardiac ultrasound)
Description: A ultrasound of the heart and pleura will be performed. This provide information on~* Left ventricular systolic function~* Left ventricular diastolic function~* Right ventricular systolic function~* Right ventricular pressure overload~* Biventricular sizes~* Pathology of the mitral- and aortic valves~* Pericardial fluid~* Gross fluid status~* Pleural effusion
Study: NCT02926807

Intervention type: OTHER
Intervention: FDG-PET Scan
Description: a 18FDG-PET to quantify vascular inflammation

Intervention type: OTHER
Intervention: FDG-PET Scan
Description: a 18FDG-PET to quantify vascular inflammation

Intervention type: OTHER
Intervention: MDCT
Description: a MDCT to calculate the Agatston score

Intervention type: OTHER
Intervention: MDCT
Description: a MDCT to calculate the Agatston score

Intervention type: OTHER
Intervention: biopsy and blood collection
Description: biopsy and blood collection to assess biomarkers

Intervention type: OTHER
Intervention: biopsy and blood collection
Description: biopsy and blood collection to assess biomarkers
Study: NCT04815837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: 1. Viewing a video promoting Human Papillomavirus (HPV) vaccination: participants will watch a 5-minute online video promoting MSM's uptake of HPV vaccination. In the video, a peer MSM discussed about the risk of contracting HPV and having anal cancers among MSM, severe consequences of HPV-related diseases, as well as the benefits of HPV vaccination. He also demonstrated the procedures of taking up HPV vaccination in the collaborative private clinics, which portrayed caring, privacy guaranteed, and non-judgmental environment.~2. Receiving the discount coupons: each participant will be given a discount coupon. By using the coupon, one can enjoy a 10% discount for taking up three doses of HPV vaccines at a collaborating private clinic.~3. Visiting the project webpage: Participants can assess the project webpage by scanning the QR code on the discount coupon.~4. Follow-up reminders: participants received five reminders at Month 1, 2, 4, 6, \& 8.
Study: NCT01216774

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strength training
Description: Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM
Study: NCT03551522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar
Description: 10 mg, 20 mg, or 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar
Description: 10 mg, 20 mg, or 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar
Description: 10 mg, 20 mg, or 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Matching placebo Capsule
Study: NCT03388814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration of bupivacaine
Description: Patients assigned to the local infiltration with bupivacaine group will receive 30 ml of 0.25% bupivacaine with 1:200,000 epinephrine. These injections will occur at the end of the mastectomy and prior to the insertion of the tissue expander implant. The local anesthetic will be injected into the chest wall and skin flaps. Attending physicians and resident physicians will receive prior instruction regarding correct placement of the local anesthetic so that it will be consistently placed in the same locations with similar volume distribution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pectoralis Nerve block
Description: Patients assigned to the pectoralis block group will receive a total of 20 ml 0.25% bupivacaine (with 1:200,000 epinephrine and 1.67 mcg clonidine per ml) in the tissue plane between the serratus anterior and the pectoralis minor muscles at approximately the level of the 4th rib and 10 ml of the same solution in the tissue plane between the two pectoralis muscles at approximately the 3rd rib under ultrasound guidance on the surgical side preoperatively.
Study: NCT02503605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biosimilar recombinant FSH
Description: Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urinary FSH
Description: Controlled ovarian stimulation with 150 IU/day urinary FSH
Study: NCT04312087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral neck sentinel lymph node biopsy
Description: Lateral neck sentinel lymph node biopsy is performed in all patients in Arm B.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified lateral neck lymph node dissection
Description: Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified lateral neck lymph node dissection
Description: Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Super selective lateral neck lymph node dissection
Description: Super selective lateral neck lymph node dissection is performed in some of the patients in Arm B (according to sentinel lymph node biopsy results).
Study: NCT05284695

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Patients undergoing elective bariatric surgery

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Patients undergoing elective bariatric surgery

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Patients undergoing elective bariatric surgery
Study: NCT03637049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050 and midazolam
Description: A single oral dose of midazolam (1 mL of 2mg/mL syrup) will be given to all subjects in Period 1 and on Day 5 of Period 2. 1200 mg of PBI-4050 (3 X 400 mg tablets) will be administered for 5 days (Day 1 to Day 5) of Period 2 and a single dose of midazolam (1 mL of 2mg/mL) on Day 5.
Study: NCT01392183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg by mouth daily in 4 week study cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benadryl
Description: 25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
Study: NCT00757315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NdYag Laser(hair removal laser) plus topical corticosteroid
Description: NdYag laser and topical corticosteroid are applied to one half of the scalp.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroid alone
Description: topical corticosteroid alone is applied to one half of the scalp
Study: NCT03791632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classical lecture style presentation
Description: classical lecture style presentation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: an intervention in the form of fun workshops
Description: an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital media intervention
Description: digital media intervention
Study: NCT02157454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website access
Description: Access to the colorectal cancer module of the website www.krankheitserfahrungen.de which provides free, reliable information about health issues by sharing people's real-life experiences
Study: NCT01920906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy and blood test
Description: Analysis of histology and gene expression in affected and unaffected skin
Study: NCT00492843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate (Bondronat)
Description: Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate (Bondronat)
Description: Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
Study: NCT01738022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of gas mixtures
Study: NCT04533711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OA-PCP Intervention
Description: The OA-PCP intervention includes brief physical activity (PA) counseling delivered via phone by a PA Coach trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA Coach will ask participants about their current physical activity level and work with them to set physical activity goals. Then, after the first call, participants in this group will receive a call about two weeks later, then at about 3 months, 6 months, 9 months and 12 months later. During these calls, the PA coach will ask participants' about their progress toward PA goals and work with them to address any barriers or challenges. The coach will also help participants to identify any programs or resources that may help them to achieve their PA goals. Participants in this group will be asked to wear a wrist-worn monitor to help them track their PA during the intervention period. Also, if participants approve, the coach will use an online program to view their PA data.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: This group will receive an intervention in the same dose (e.g., number and duration of phone calls and emails) as the OA-PCP group, but the content will not be PA-specific. During the first call, the Coach will discuss 2 topics, for which the amount of content parallels call #1 for the OA-PCP: What is OA? OA Diagnosis and OA Risk Factors. During the second call, the Coach will discuss the topic of Health Care Providers and Overview of OA Treatment Guidelines. Call topics for 3, 6, 9 and 12- month follow-up calls will be: Pain Medications, Mechanical Treatments (e.g., knee braces, footwear, joint protection), Complimentary and Alternative Therapies and discussion of OA and Mental Health, Sleep and Fatigue.
Study: NCT00408863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tibolone
Description: tibolone 2.5 mg/day
Study: NCT01619930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation without rationale
Description: A behavioral activation program without TRAP-TRAC rationale, but with some encouragement provided (Activate yourself and feel better!). Approximately 15 minutes of electronic therapist support will be included per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation without rationale
Description: A behavioral activation program without TRAP-TRAC rationale, but with some encouragement provided (Activate yourself and feel better!). Approximately 15 minutes of electronic therapist support will be included per week.
Study: NCT02874664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab Tesirine
Description: Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
Study: NCT00408863

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03099733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: text message
Description: Participants will receive text message assessment and tailored intervention messages daily over the 14-day/two-week study period.
Study: NCT04850183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on disease management on the quality of life, and anxiety and depression about Rheumatoid Arthritis
Description: The patients in the intervention group participated in a one-to-one training program consisting of a 30-min onset session.
Study: NCT01475734

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection
Study: NCT03077373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling letter
Description: The brief counseling letter intervention aiming to reduce physical inactivity, sedentary time in leisure time as well as smoking is based on behavior change theories (Transtheoretical model of health behavior change and Health Action Process Approach).~The computerized intervention system includes up to six interactions with participants. Recurrent assessments are initiated by the system and provide data for scheduling the proceeding intervention steps and selection of relevant content. Physical activity, sedentary time, smoking, and motivational measures to change or maintain behaviors according to the recommendations will be monitored over time and used to provide feedback in the form of letters.
Study: NCT02490696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miso PET scan
Description: 2 PET scans will be performed before surgery : the first one with F-Miso tracer and the second, 24 hours later, with FAZA tracer
Study: NCT03242954

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autonomous minor consent
Description: Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
Study: NCT02272556

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRS during hyperglycemic clamp
Description: All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRS during hyperglycemic clamp
Description: All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRS during hyperglycemic clamp
Description: All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of Metabolites in cerebrospinal fluid
Description: All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of Metabolites in cerebrospinal fluid
Description: All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of Metabolites in cerebrospinal fluid
Description: All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid
Study: NCT04910178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: tablets to be taken orally once a day
Study: NCT02490696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FAZA PET scan
Description: 2 PET scans will be performed before surgery : the first one with FAZA tracer and the second, 24 hours later, with F-Miso tracer
Study: NCT04672109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Dual/Cathodal/Anodal/Sham tDCS will be applied in 2 mA, 20 mins. All experiments will be performed in random order for each subject.
Study: NCT04910178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: tablets to be taken orally twice a day